Memantine Market Size, Share, Outlook, and Opportunity Analysis, 2018– 2026


Posted February 4, 2021 by SANJAYCMI

Memantine Market Report- 2020 Analyses competitive environment such as key players, future trends, growths, challenges and acquisitions in the market.
 
Memantine Market, by Formulation (Tablet and Capsule), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) -Size, Share, Outlook, and Opportunity Analysis 2018 – 2026

Memantine is a non-acetyl cholinesterase inhibitor drug that aids in treatment of Alzheimer's disease. The drug received European marketing approval in 2002 and the U.S. Food and Drug Administration (U.S FDA) approval in 2003. The generic versions of the drugs are available since 2015. Memantine aids in treatment of moderate to severe dementia associated with Alzheimer's disease. However the drug may show a severe skin reaction called Stevens-Johnson syndrome (associated with painful blisters on the skin) after prolonged use.

Memantine Market– Drivers

Increasing number of pipeline studies for use of memantine are expected to boost growth of the memantine market. For instance, in September 2016, Lille University Hospital started phase I clinical study for assessing the effects of memantine on cognitive behavior of patients associated with Alzheimer’s disease. The study is estimated to be completed by February 2019.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2255

Furthermore, Suven Life Sciences Limited is undergoing phase II clinical study for the comparative study on safety and efficacy of SUVN-502 along with memantine HCl and donezepil HCl for treating moderate Alzheimer’s disease. The study was started in September 2015 and is expected to be completed in May 2019.

Memantine Market– Restraint

Increasing number of expired patents of drugs is a major factor hindering growth of the global memantine market. For instance, according Merz Pharmaceuticals, a Germany-based company, in October 2018, overall licensing income during patented period for memantine decreased due to expiration of patent protection in a majority of markets. For instance, according to Merz Pharmaceuticals, the U.S. licensing income for memantine declined to US$ 138.07 million in 2017-18 compared to US$ 183.34 million in year 2016.

Memantine Market– Regional Analysis

On the basis of region, the global memantine market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/memantine-market-2255

North America is expected to hold dominant position in the global memantine market, owing to increasing number of generic versions of memantine in the U.S. market. For instance, in February 2018, Lupin Limited announced the launch of its Memantine Hydrochloride Extended-Release Capsules in the U.S. market. The capsules are available in 7mg, 14mg, 21mg, and 28mg, for which company has received an approval from the U.S. FDA. These are indicated for the treatment of moderate to severe dementia of the Alzheimer’s disease.

Furthermore, Asia Pacific is expected to witness significant growth in the global memantine market, owing to increasing focus of key players in manufacturing memantine tablets. For instance, in October 2018, Dr. Reddy’s Laboratories launched memantine hydrochloride tablets in the Indian market. They are available in 5mg and 10mg, equivalent to generic version of Namenda tablets, which were already available in the U.S. market in July 2015.

Memantine Market– Competitive Analysis

Key players operating in the global memantine market include, Merz Pharmaceuticals, Lupin Limited, Allergan plc. Novartis AG, Daiichi Sankyo Company, Limited, Ono Pharmaceutical Co Ltd., Eisai Co., Ltd., H. Lundbeck A/S, Dr. Reddy’s Laboratories, and Johnson & Johnson Services, Inc.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/2255

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
mailto:[email protected]
U.S. Office:
Name: Mr. Shah
Coherent Market Insights 1001 4th Ave,
# 3200 Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Coherent Market Insights
Phone +1-206-701-6702
Business Address 1001 4th Ave
# 3200 Seattle, WA 98154, U.S.
Country United States
Categories Health , Marketing , Research
Tags memantine , memantine market , memantine market outlook
Last Updated February 4, 2021